t863

T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells. IC50 value: Target: DGAT1 T863 (DGAT-3) causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice.

CFT8634 is an orally active and selective degrader targeting BRD9, with effects on the proliferation of SMARCB1-deficient cancer cell lines. CFT8634 induces the formation of a ternary complex with BRD9 and E3 ligase, inducing BRD9 ubiquitination and subsequent degradation by the proteasome.

(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular proliferation [1].

Baclofen hydrochloride (4-amino-3-(4-chlorophenyl)butanoic acid hydron chloride) is a GAMMA-AMINOBUTYRIC ACID derivative that is a specific GABA-B RECEPTORS agonist. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.

Pyridostigmine(Regonol) is an acetylcholinesterase inhibitor that can treat myasthenia gravis by increasing acetylcholine at the postsynaptic motor endplate.

9-FLUORENOL is a dopamine reuptake inhibitor with IC50 of 9 µM, and a major metabolite of a compound developed as a wakefulness-promoting agent.

NPC 15199 (FMOC-L-Leucine) is an anti-inflammatory agent.

8-Bromotheophylline (Bromotheophylline) is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, 8-Bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome

DMNB (6-Nitroveratraldehyde) is DNA-dependent protein kinase (DNA-PK) inhibitor with IC50 of 15 μM, an enzyme involved in the non-homologous end-joining (NHEJ) pathway of double-stranded DNA break (DSB) repair in human cells.

DPP1-IN-1 (compound 1) serves as a potent DPP1 inhibitor and is utilized in the study of bronchiectasis [1].

DPP1-IN-1 hydrate, a DPP1 inhibitor (IC 50: 1.6 nM), exhibits excellent bioavailability and pharmacokinetic properties, making it suitable for investigating inflammatory diseases [1].

DS43260857 is a potent NaV1.7 inhibitor with high inhibitory effects on both human and mouse NaV1.7, exhibiting IC50 values of 6.6 μM for hNaV1.1, 14 μM for hNaV1.5, 0.015 μM for hNaV1.7, and 0.061 μM for mNaV1.7 [1].

DS55980254 is a highly effective and specific inhibitor of phosphatidylserine synthase 1 (PTDSS1) [1].

DYB-03 is an orally active HIF-1α/EZH2 inhibitor that inhibits migration, invasion, and angiogenesis of lung cancer cells and HUVECs in vitro and in vivo, and induces apoptosis in 2-ME2- and GSK126-resistant A549 and H460 cells [1].

E3 Ligase Ligand 21 (compound 2), a cereblon binder, facilitates the degradation of Ikaros or Aiolos via the ubiquitin proteasome pathway [1].

E3 Ligase Ligand 22 (compound 139) serves as a cereblon binder, facilitating the degradation of Ikaros or Aiolos via the ubiquitin proteasome pathway [1].

E3 Ligase Ligand-linker Conjugate 15, a conjugate of E3 ubiquitin ligase ligand-linker, can be utilized for synthesizing complete PROTACs molecules.

E3 Ligase Ligand-linker Conjugate 28, a combination of E3 ligase ligand and linker comprising Thalidomide and its corresponding linker, acts as a Cereblon ligand to recruit the CRBN protein and serves as a crucial intermediate in synthesizing complete PROTAC molecules.

E3 Ligase Ligand-Linker Conjugate 34 comprises Thalidomide linked to a corresponding linker, serving as a conjugate between an E3 ligase ligand and a linker. This compound acts as a cereblon ligand, recruiting the CRBN protein and functioning as an essential intermediate in the synthesis of complete PROTAC molecules.

E3 ligase Ligand-Linker Conjugate 39, a conjugate of an E3 ligase ligand and linker, comprises Thalidomide and the corresponding Linker. This conjugate can act as a Cereblon ligand to recruit CRBN protein and serve as a crucial intermediate in the synthesis of complete PROTAC molecules.

E3 Ligase Ligand-linker Conjugate 45, a conjugate of E3 ligase ligand and linker, consists of Thalidomide and the corresponding Linker. It can serve as a Cereblon ligand to recruit CRBN protein and acts as a key intermediate for synthesizing complete PROTAC molecules.

E3 Ligase Ligand-linker Conjugate 48, a conjugate of E3 ubiquitin ligase ligand-Linker, is utilized for synthesizing complete PROTACs molecules.

E3 Ligase Ligand-linker Conjugate 5, a combination of an E3 ligase ligand and linker, comprises Thalidomide and its specific Linker. This conjugate acts as a Cereblon ligand to attract the CRBN protein and functions as a crucial intermediate in the production of full PROTAC molecules.

E3 Ligase Ligand-linker Conjugate 51, a compound comprising Thalidomide and its corresponding linker, functions as a Cereblon ligand to recruit CRBN protein and is a crucial intermediate in the synthesis of complete PROTAC molecules.